{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T13:40:13Z","timestamp":1793194813750,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Refractory non-malignant ureterostenosis is challenging to treat. The experience to treat the stenosis primarily cause by retroperitoneal fibrosis with the Resonance and Allium metallic stent is still limited. We aim to evaluate the efficacy and safety of these two stents and provide alternative treatment options.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A retrospective study was conducted for patients with non-malignant ureterostenosis and treated with the Resonance and Allium stents from March 2011 to September 2020 in our department. The efficacy was evaluated by the change of serum creatinine, glomerular filtration rate (GFR), the proportion of GFR of the affected side and hydronephrosis grade. The safety was evaluated by postoperative presence of moderate or severe overactive bladder (OAB), recurrent urinary infection, pain, stent displacement, encrustation and re-obstruction.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>33 patients were eligible for the study, including 18 cases treated by the Resonance stents and 15 patients treated by the Allium stents. The patients of two groups had similar age and gender proportion. The cause of ureterostenosis was mainly retroperitoneal fibrosis in both groups but the Resonance group had more idiopathic cases. Follow-up time was significantly longer in the Resonance group than the Allium group (36.2\u2009\u00b1\u200924.0 vs 9.4\u2009\u00b1\u20095.0\u00a0months, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Both groups showed improvement or maintenance of serum creatinine level, GFR, the GFR proportion of the affected side and hydronephrosis grade after treatment. The Resonance group presented significant higher incidence of moderate or severe OAB, recurrent urinary infection and pain, while the Allium group showed significant more cases of re-obstruction.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Both the Resonance and Allium stent can relieve the non-malignant refractory ureterostenosis effectively. The Resonance stent may cause more irritable symptoms while the Allium stent may have a higher rate of re-obstruction. The long term efficacy and safety of the Allium stent in treating non-malignant refractory ureterostenosis requires further study.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12894-021-00815-6","type":"journal-article","created":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T07:03:09Z","timestamp":1617778989000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["The Resonance and the Allium ureteral stents in the treatment of non-malignant refractory ureterostenosis"],"prefix":"10.1186","volume":"21","author":[{"given":"Wei","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianying","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongwen","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,7]]},"reference":[{"issue":"1","key":"815_CR1","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.juro.2008.08.125","volume":"181","author":"MS Christman","year":"2009","unstructured":"Christman MS, L\u2019esperance JO, Choe CH, Stroup SP, Auge BK. Analysis of ureteral stent compression force and its role in malignant obstruction. J Urol. 2009;181(1):392\u20136.","journal-title":"J Urol"},{"key":"815_CR2","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1089\/end.2006.0315","volume":"21","author":"SD Blaschko","year":"2007","unstructured":"Blaschko SD, Deane LA, Alfred Krebs BSF, et al. In-vivo evaluation of flow characteristics of novel metal ureteral stent. J Endourol. 2007;21:780\u20134.","journal-title":"J Endourol"},{"key":"815_CR3","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.juro.2008.08.125","volume":"181","author":"MS Christman","year":"2009","unstructured":"Christman MS, L\u2019esperance JO, Choe CH, et al. Analysis of ureteral stent compression force and its role in malignant obstruction. J Urol. 2009;181:392\u20136.","journal-title":"J Urol"},{"issue":"2","key":"815_CR4","doi-asserted-by":"publisher","first-page":"87","DOI":"10.5301\/uj.5000249","volume":"85","author":"M Oderda","year":"2018","unstructured":"Oderda M, Lacquaniti S, Fasolis G. Allium stent for the treatment of a malignant ureteral stenosis: a paradigmatic case. Urologia. 2018;85(2):87\u201390.","journal-title":"Urologia"},{"issue":"6","key":"815_CR5","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.urology.2007.02.004","volume":"69","author":"DA Duchene","year":"2007","unstructured":"Duchene DA, Winfield HN, Cadeddu JA, Clayman RV, Gomella LG, Kavoussi LR, Mikhail AA, Park S, Permpongkosol S, Shalhav AL. Multi-institutional survey of laparoscopic ureterolysis for retroperitoneal fibrosis. Urology. 2007;69(6):1017\u201321.","journal-title":"Urology"},{"issue":"2","key":"815_CR6","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.urology.2007.10.026","volume":"71","author":"MD Stifelman","year":"2008","unstructured":"Stifelman MD, Shah O, Mufarrij P, Lipkin M. Minimally invasive management of retroperitoneal fibrosis. Urology. 2008;71(2):201\u20134.","journal-title":"Urology"},{"key":"815_CR7","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.eururo.2009.02.004","volume":"57","author":"E Liatsikos","year":"2010","unstructured":"Liatsikos E, Kallidonis P, Kyriazis I, et al. Ureteral obstruction: is the full metallic double-pigtail stent the way to go? Eur Urol. 2010;57:480\u20137.","journal-title":"Eur Urol"},{"issue":"5","key":"815_CR8","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1016\/j.juro.2010.12.035","volume":"185","author":"Y Ito","year":"2011","unstructured":"Ito Y, Kikuchi E, Tanaka N, Miyajima A, Mikami S, Jinzaki M, Oya M. Preoperative hydronephrosis grade independently predicts worse pathological outcomes in patients undergoing nephroureterectomy for upper tract urothelial carcinoma. J Urol. 2011;185(5):1621\u20136.","journal-title":"J Urol"},{"issue":"9506","key":"815_CR9","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S0140-6736(06)68035-5","volume":"367","author":"A Vaglio","year":"2006","unstructured":"Vaglio A, Salvarani C, Buzio C. Retroperitoneal fibrosis. Lancet. 2006;367(9506):241\u201351.","journal-title":"Lancet"},{"issue":"7","key":"815_CR10","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1681\/ASN.2015101110","volume":"27","author":"A Vaglio","year":"2016","unstructured":"Vaglio A, Maritati F. Idiopathic retroperitoneal fibrosis. J Am Soc Nephrol. 2016;27(7):1880\u20139.","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"815_CR11","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.amjmed.2005.02.004","volume":"118","author":"H Oshiro","year":"2005","unstructured":"Oshiro H, Ebihara Y, Serizawa H, et al. Idiopathic retroperitoneal fibrosis associated with immunohematological abnormalities. Am J Med. 2005;118(7):782\u20136.","journal-title":"Am J Med"},{"issue":"4","key":"815_CR12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1741-7015-4-23","volume":"6","author":"GH Neild","year":"2006","unstructured":"Neild GH, Rodriguez-Justo M, Wall C, Connolly JO. Hyper-IgG4 disease: report and characterisation of a new disease. BMC Med. 2006;6(4):23.","journal-title":"BMC Med"},{"issue":"6","key":"815_CR13","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.eururo.2016.10.046","volume":"71","author":"A Fernando","year":"2017","unstructured":"Fernando A, Pattison J, Horsfield C, D\u2019Cruz D, Cook G, O\u2019Brien T. [18F]-fluorodeoxyglucose positron emission tomography in the diagnosis, treatment stratification, and monitoring of patients with retroperitoneal fibrosis: a prospective clinical study. Eur Urol. 2017;71(6):926\u201333.","journal-title":"Eur Urol"},{"key":"815_CR14","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1016\/j.juro.2011.02.008","volume":"185","author":"AD Benson","year":"2011","unstructured":"Benson AD, Taylor ER, Schwartz BF. Metal ureteral stent for benign and malignant ureteral obstruction. J Urol. 2011;185:2217\u201322.","journal-title":"J Urol"},{"key":"815_CR15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1586\/erp.09.74","volume":"10","author":"AJ Polcari","year":"2010","unstructured":"Polcari AJ, Hugen CM, L\u00f3pez-Huertas HL, et al. Cost analysis and clinical applicability of the resonance metallic ureteral stent. Expert Rev Pharmacoecon Outcomes Res. 2010;10:11\u20135.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"815_CR16","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1089\/end.2009.0192","volume":"24","author":"HL L\u00f3pez-Huertas","year":"2010","unstructured":"L\u00f3pez-Huertas HL, Polcari AJ, Acosta-Miranda A, et al. Metallic ureteral stents: a cost-effective method of managing benign upper tract obstruction. J Endourol. 2010;24:483\u20135.","journal-title":"J Endourol"},{"issue":"3","key":"815_CR17","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/j.1464-410X.2010.09842.x","volume":"108","author":"HJ Wang","year":"2011","unstructured":"Wang HJ, Lee TY, Luo HL, et al. Application of resonance metallic stents for ureteral obstruction. BJU Int. 2011;108(3):428\u201332.","journal-title":"BJU Int"},{"issue":"11","key":"815_CR18","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1089\/end.2012.0279","volume":"26","author":"B Moskovitz","year":"2012","unstructured":"Moskovitz B, Halachmi S, Nativ O. A new self-expanding, large-caliber ureteral stent: results of a multicenter experience. J Endourol. 2012;26(11):1523\u20137.","journal-title":"J Endourol"},{"issue":"10","key":"815_CR19","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1089\/end.2013.0281","volume":"27","author":"SE Elsamra","year":"2013","unstructured":"Elsamra SE, Motato H, Moreira DM, et al. Tandem ureteral stents for the decompression of malignant and benign obstructive uropathy. J Endourol. 2013;27(10):1297\u2013302.","journal-title":"J Endourol"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-021-00815-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12894-021-00815-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-021-00815-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T07:03:20Z","timestamp":1617779000000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-021-00815-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,7]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["815"],"URL":"https:\/\/doi.org\/10.1186\/s12894-021-00815-6","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,7]]},"assertion":[{"value":"21 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Xuanwu Hospital, Capital Medical University and conducted in accordance with the standards laid down in the declaration of Helsinki. All patients provided informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"53"}}